Asapiprant (S555739) is a novel, potent and selective Prostaglandin D2receptor 1 (DP1) receptor antagonist (Ki = 0.44 nM) with the potential for treating allergic airway diseases. Asapiprant showed high affinity and selectivity for the DP1 receptor over other targets. After asapiprant treatment, a significant suppression of antigen-induced nasal resistance, nasal secretion, and cell infiltration in nasal mucosa was observed. Further, treatment with asapiprant suppressed antigen-induced asthmatic responses, airway hyper-responsiveness, and cell infiltration and mucin production in lung. These results show that asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases.

纯度：≥98%

CAS：932372-01-5